Who are Eplerenone vs Amlodipine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eplerenone-vs-amlodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Eplerenone vs Amlodipine — Competitive Intelligence Brief

Eplerenone vs Amlodipine (Eplerenone vs Amlodipine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine). Area: Cardiovascular.

marketed Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Eplerenone vs Amlodipine (Eplerenone vs Amlodipine) — Brigham and Women's Hospital. This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eplerenone vs Amlodipine TARGET	Eplerenone vs Amlodipine	Brigham and Women's Hospital	marketed	Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine)	Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) class)

Brigham and Women's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eplerenone vs Amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/eplerenone-vs-amlodipine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab